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Background: Oxidized linoleic acid metabolites (OLAMs) are a class of endogenous agonists to the transient
receptor potential V1 (TRPV1) receptor. Although TRPV1 mediates inflammatory heat hyperalgesia, it is not known if
the OLAMs contribute to the peripheral activation of this receptor during tissue inflammation. In the present study,
we evaluated whether the OLAM system is activated during inflammation and whether cytochrome P450 enzymes
mediate OLAM contributions to heat hyperalgesia using the complete Freund’s adjuvant (CFA) model of
inflammation.
Results: Our results demonstrate that the intraplantar (ipl) injection of anti-OLAM antibodies significantly reversed
CFA-induced heat hyperalgesia. Moreover, application of lipid extracts from inflamed rat skin to cultured sensory
neurons triggered a significant release of iCGRP that is blocked by co-treatment with I-RTX, a TRPV1 antagonist. To
determine the role of CYP enzymes in mediating OLAM effects, we used a broad spectrum CYP inhibitor,
ketoconazole. Pretreatment with ketoconazole inhibited the release of TRPV1 agonists in lipid extracts from
inflamed skin and significantly reversed CFA-induced heat hyperalgesia by a peripheral mechanism of action.
Moreover, the ipl injection of linoleic acid to rats 24 hr after CFA evoked spontaneous nocifensive behaviors that
were significantly reduced by capsazepine, by knockout of the TRPV1 gene, or by pretreatment with either
anti-OLAM antibodies or ketoconazole.
Conclusions: Taken together, our data suggests that OLAMs contribute to inflammatory nociception in the
periphery and that cytochrome P450 enzymes play a crucial role in mediating OLAM contributions to inflammatory
heat hyperalgesia.
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Tissue injury leads to the release of inflammatory med-
iators that sensitize and activate peripheral nociceptors
resulting in an afferent barrage to dorsal horn neurons.
The transient receptor potential vanilloid subtype-1
(TRPV1) receptor is a ligand-gated cation channel that
is expressed on certain nociceptors, is activated by nox-
ious stimuli such as heat, and mediates inflammatory
heat hyperalgesia [1,2]. During tissue inflammation,
TRPV1 activity is modulated by several classes of* Correspondence: Hargreaves@uthscsa.edu
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reproduction in any medium, provided the ormediators such as arachidonic acid metabolites, brady-
kinin, nerve growth factor (NGF), as well as prostaglan-
dins [3-5].
One class of endogenous mediators that activate
TRPV1 consists of oxidized linoleic acid metabolites
(OLAMs), namely, 9-and 13-hydroxy-10E,12Z-octadeca-
dienoic acid (9-HODE and 13-HODE) as well their
metabolites, 9-oxoODE and 13-oxoODE. Previous stud-
ies have reported that the OLAMs are synthesized under
inflammatory conditions such as atherosclerosis and
rheumatoid arthritis [6-8] as well as shown to be
increased in serum of patients with chronic pancreatitis
[9]. In addition, several groups have detected OLAMs in
endothelial cells, macrophages and neutrophils [10,11],
cell types activated during tissue inflammation. However,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vate TRPV1 in both peripheral tissues and spinal dorsal
horn [12,13]. Importantly, there is a gap in knowledge of
this system since it is not known whether OLAMs con-
tribute to activation of peripheral TRPV1 during tissue
inflammation.
In the current study, we investigated the peripheral ac-
tion of OLAMs in the rat complete Freund’s adjuvant
(CFA) model of inflammation. Previously, we have
shown that CYP inhibtors block linoleic acid activation
of TRPV1 in cultured sensory neurons [14], suggesting
that CYP isozymes mediate the formation of TRPV1-
active linoleic acid metabolites. Accordingly, we con-
ducted parallel in vitro and in vivo studies to determine
whether peripheral CYPs in inflamed tissue mediate
OLAM activation of TRPV1.
Methods
Animals
All protocols were approved by the Institutional Animal
Care and Use Committee of the University of Texas
Health Science Center at San Antonio. Male Sprague–
Dawley rats (Charles River Laboratories, Inc., Wilming-
ton, MA, USA) were used for all the studies except in
one experiment where wild-type and TRPV1 knockout
C57BL/6 mice (Jackson Laboratories) were used. Ani-
mals were housed for at least 7 days prior to the
experiments.
Drugs
Ketoconazole, iodo-resinferatoxin (I-RTX) and capsazepine
(CPZ) were purchased from Tocris (Ellsville, Missouri,
USA). The goat anti-9-HODE and anti-13-HODE anti-
bodies were purchased from Oxford Biomedical Research
(Rochester Hills, MI). As a control, a non-specific goat IgG
antibody was purchased from Sigma Aldrich (St. Louis,
MO). Linoleic acid (LA) was purchased from Cayman Che-
micals (Ann Arbor, MI). Ketoconazole was diluted in 32%
methylpyrrolidinone (MPL)/Hank’s balanced salt solution
(HBSS) to make a stock of 18 mM and further diluted in
HBSS on the day of each experiment. I-RTX stock (2 mM)
was made in 100% ethanol that was further diluted in HBSS
on the day of use. CPZ was diluted in 20% DMSO/80%
mineral oil. The linoleic acid solution was dried under ni-
trogen gas to remove ethanol, and resuspended in HBSS
immediately before the experiment. The pH of this solution
was confirmed to be 7.4 to ensure no activation of TRPV1
by protons.
TG cultures
For calcium imaging experiments, 1-day-old cultures of
rat trigeminal ganglia (TG) were used. TG’s were dis-
sected from normal rats and plated on poly-D-lysine/
laminin coated glass cover slips (BD Biosciences, SanJose, CA, USA) and grown in the presence of 10% FBS
and 100 ng/mL NGF (Harlan, Indianapolis, IN, USA) as
described previously [15]. For determination of CGRP
release, TGs from three rats were cultured as described
[16] and plated on 24-well poly-d-lysine-coated plate
yielding ~8000 cells per well. The media were replaced
at the end of 24 h and then 48 h later. All the experi-
ments were performed on day 5 of the neuronal
cultures.
Calcium imaging
Fluorescence imaging to measure calcium accumulations
in sensory neurons was performed as described [15].
The TG cultures were incubated with the calcium-
sensitive dye, Fura-2 AM (2 μm; Molecular Probes,
Carlsbad, CA, USA) in Hanks modified buffer. Fluores-
cence was detected with a Nikon TE 2000U microscope
fitted with a × 40/1.35 NA Fluor objective. Data were col-
lected and analyzed with MetaFluor Software (Universal
Imaging Corporation, Downingtown, PA, USA). The net
changes in calcium influx were calculated by subtract-
ing the intracellular calcium [Ca2+]i level (mean value
collected for 60 s prior to agonist addition) from the
peak [Ca2+]i value achieved after exposure to the
agonist. Cells were pretreated with vehicle or ketoco-
nazole (30uM) for 15 min followed by the addition of
linoleic acid (1 mM) in the presence of the ketocona-
zole for 2 min. At the end of each experiment, a so-
lution containing KCl (250 mM) was applied after
linoleic acid application to ensure sampling of viable
neurons. The ratio of 340/360 above 0.03 was consid-
ered to be a positive response for calcium influx.
Model of inflammation
Male rats were anesthetized with isoflurane and injected
with 50 μl of a 1:1 mixture of complete CFA (Sigma) in
saline into right hind paw. At 24 hours, the inflamed tis-
sue were either used to collect biopsy punches for lipid
extract preparation or behavioral tests with inflamed
hind paws.
Preparation of lipid extracts
Rats were injected with CFA and at 20 hours, the ani-
mals were injected either with vehicle or ketoconazole
(9.5 mg/kg) s.c. underneath the neck. Four hours after
drug injection, the animals were decapitated and the
inflamed hind paw tissues were collected by 6 mm bi-
opsy punches. The tissues were diced and transferred to
HBSS modified with CaCl2 2 mM, NaHCO3 4 mM,
HEPES 10 mM, and dextrose 10 mM (pH 7.4) for
30 min at 37°C to wash and equilibrate. The tissues were
then transferred to fresh HBSS buffer containing either
vehicle or ketoconazole (150uM) and incubated at 37°C
for 1 h. The superfusates were collected and subjected
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™ column
(Waters, Inc) as described previously [12] and dried
under a stream of N2. The dried samples were then
resuspended in HBSS and applied to cultured sensory
neurons for determining CGRP release.
CGRP release assay and Radioimmunoassay
Calcitonin gene-related peptide (CGRP) release from TG
neurons was determined as described previously [16].
Briefly, the experiments were conducted in HBSS solu-
tion using 5 day old TG cultures. After initial wash and
baseline collection, the neurons were pretreated with ei-
ther vehicle or I-RTX for 15 min prior to a 15 min ex-
posure to the lipophilic extracts from inflamed skin. The
media were collected and subjected to radioimmuno-
assay (RIA) for CGRP. All experiments were performed
three times.
Behavioral testing
All observers were blinded to treatment allocation. Ther-
mal allodynia was measured using the radiant heat test as
described previously [17]. To study the effects of HODE
antibodies on CFA-induced heat hyperalgesia, 24 h
inflamed rat hind paws were injected with 50ul of a mix-
ture of anti-9-HODE (25 ug) and anti-13-HODE (25 ug)
antibodies or 50ul of same amount of heat denatured
antibodies. Thermal thresholds were measured 15, 30
and 60 min after injection. To study the effect of ketoco-
nazole on CFA-induced heat hyperalgesia, vehicle or
ketoconazole (4ug) was injected once 30 s prior to CFA
injection in the ipsilateral hind paw and once 24 h later.
Thermal thresholds were measured 1 h after the second
ketoconazole injection. In a separate experiment, vehicle
or ketoconazole (same dose) was injected in the contra-
lateral paw 30 seconds before and 24 hours after CFA in-
jection. Thermal hyperalgesia was measured 1 h later.
Nocifensive behavior was carried out as described pre-
viously [18] to study the effect of linoleic acid injection
in inflamed rat hind paws. LA (10, 100 or 1,000 ug) or
vehicle (50 uL) was injected ipl into normal and
inflamed rat hindpaws and nocifensive behavior (defined
as spontaneous flinching or flexion movements of the
treated hind paw) was recorded every 2 min up to a total
of 15 min. Similarly, LA-evoked nocifensive behavior
was also tested in wild-type and TRPV1 KO mice. We
then conducted three studies to determine the mechan-
ism of LA-induced nocifensive behavior in rats after
CFA inflammation. In all three studies rats were injected
with CFA into the hind paw 24 h prior to the experi-
ment. In the first study, rats were treated with capsaze-
pine (50 mg/kg) or veh (sc), followed 1 hr later with LA
injection. In the second study, rats were treated with a
combination of anti-9- and anti-13-HODE antibodies
(25 ug each) or non-specific goat IgG (ipl), followed10 minutes later with LA injection. In the third study,
rats were injected with ketoconazole (4ug) or veh (ipl)
30 minutes prior to LA injection.
Statistics
Data are presented as mean ± SEM. Statistical analyses
were performed using either a 2-tailed Student’s t test or
one-way ANOVA with Neuman-Keul’s post-hoc test. A
statistically significant difference was defined as P < 0.05.
Error bars are S.E.M.
Results
OLAMs contribute to inflammatory heat hyperalgesia that
is reduced by CYP inhibition
To evaluate whether peripheral OLAMs contribute to in-
flammatory heat hyperalgesia, we injected a combination
of anti-9-HODE and anti-13-HODE antibodies, or a mix-
ture of the heat-denatured antibodies by the ipl route
and blinded observers tested their effect on heat hyper-
algesia. As expected (Figure 1A and 1B), CFA induced a
significant heat hyperalgesia that was still evident at 24 h.
Interestingly, injection of the HODE antibodies
(Figure 1A), but not the heat denatured antibodies
(Figure 1B), significantly reversed heat hyperalgesia for
up to 30 min after ipl injection. Since this represented a
complete reversal of heat hyperalgesia, the data are con-
sistent with the hypothesis that peripheral OLAMs play a
crucial role in inflammatory heat hyperalgesia. In con-
trast, there was no change in thermal latencies in the un-
inflamed hindpaws that were contralateral to the hind-
paws receiving either the mixture of antibodies
(Figure 1C) or the denatured antibodies (Figure 1D).
Next, we studied the role of CYP enzymes in regulat-
ing OLAM-mediated thermal hyperalgesia during in-
flammation. The ipl injection of ketoconazole into
inflamed paws significantly reduced inflammatory heat
hyperalgesia 1 h after drug injection compared to the ve-
hicle injected group (Figure 2A and 2B). This effect is
peripherally mediated since injection of ketoconazole
into the contralateral hindpaws had no effect on the
inflamed paws (Figure 2C “Inflamed” versus Figure 2D
“Inflamed”). Moreover, the effect of ketoconazole was
restricted to reversing heat hyperalgesia in inflamed
hindpaws, with no changes observed in thermal antino-
ciception in normal hindpaws, since local injection of
ketoconazole into the un-inflamed hindpaws had no ef-
fect on paw withdrawal latencies (Figure 2C “Contralat-
eral” versus Figure 2D “Contralateral).
Ketoconazole inhibits the release of endogenous TRPV1
agonists
We previously have reported that LA-evoked calcium
accumulation in sensory neurons is TRPV1-dependent
and is blocked by compounds that inhibit cytochrome
Figure 1 Effect of HODE Antibodies on CFA-induced Thermal Allodynia. A 50uL solution of 1:1 CFA:saline was injected into the right hind
paw of rats and 24 h later, heat hyperalgesia was measured using the radiant heat test on the inflamed paws as well as in the contralateral
(un-inflamed) paws. Following this, in one group of animals, 25ug of anti- 9-HODE and 25ug of anti-13-HODE antibodies were injected into the
inflamed paw. Heat hyperalgesia was measured at 15, 30 and 60 minutes after antibody injection in the A. inflamed paw and B. in the
contralateral paw. Similarly, another group of animals was injected with same amount of denatured HODE antibodies. Heat hyperalgesia was
measured at 15, 30 and 60 minutes after antibody injection in the C inflamed paw and D. in the contralateral paw. n = 6 was used for each
group in all the experiments and mean of all n’s is plotted. Data were analyzed using one-way ANOVA with Neuman-Keuls Post-hoc test. Error
Bar: S.E.M.
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hydroguaiaretic acid and diphenyliodonium [14]. How-
ever, several of these compounds are not suitable for
in vivo studies and so we evaluated the well known
CYP inhibitor, ketoconazole. Cultured TG neurons that
were pretreated with vehicle followed by stimulation
with LA exhibited a three-fold increase in [Ca]i com-
pared to noise (Figure 3A). In contrast, pretreatment
with ketoconazole abolished the effect of LA on trig-
gering increased [Ca]i (p < 0.005). Thus, ketoconazole
inhibits the formation of TRPV1-active metabolites of
linoleic acid.
We next evaluated whether ketoconazole alters the
release of endogenous TRPV1 agonists from inflamed
tissues (Figure 3B). At 24 hr after injection of
CFA, inflamed tissue biopsies were collected and lipids
were extracted and isolated using reverse phasechromatography. The application of the resuspended
extracts to cultured TG neurons evoked a ten-fold in-
crease in CGRP release that was significantly attenuated
in extracts co-treated with the TRPV1 antagonist,
I-RTX. These data support the release of endogenous
TRPV1 agonists during CFA inflammation. To deter-
mine if these substances were released by oxidative
enzymes, a separate group of animals received in vivo
administration of ketoconazole prior to biopsy collection
with continued exposure to ketoconazole during the
ex vivo extraction process. The resuspended extracts
were then applied onto TG cultures with a significant,
although incomplete, inhibition of CGRP release. Taken
together, these data indicate endogenous TRPV1 ago-
nists are released during CFA inflammation and that
about one-half of the activity can be attributed to a
ketoconazole-sensitive mechanism.
Figure 2 Effect of Ketoconazole on CFA-induced Thermal Allodynia. A 50uL solution of 1:1 CFA:saline was injected into the right hind paw
of rats and 24 hours later, heat hyperalgesia was measured using the radiant heat test in the inflamed paws as well as in the contralateral paws.
As noted, ketoconazole (4ug) was injected 30 sec prior to CFA injection and 24 hours later, thermal allodynia was measured in the A. inflamed
paw and in the contralateral paw, following which another injection of ketoconazole (4ug) was injected in the inflamed paw. Heat hyperalgesia
was tested at 30 and 60 minutes after second injection in the A inflamed paw and in the contralateral paw. In a separate group of animals,
vehicle was injection 30 seconds prior to CFA injection. Heat hyperalgesia tested at 24 hours in the B. inflamed as well as contralateral paws,
following which another vehicle injection was given and heat hyperalgesia tested at 30 and 60 minutes in the B. inflamed as well as in the
contralateral paws. For data set C and D, the experiment was performed in the similar fashion as 2A and B, except C. ketoconazole or D. vehicle
was injected in the un-inflamed paw and heat hyperalgesia measured in ipsilateral paw (inflamed) as well as contralateral paw, 30 and
60 minutes after second injection. n = 6 was used for each group in all the experiments and mean of all n’s is plotted. Data were analyzed using
one-way ANOVA with Neuman-Keuls Post-hoc test. Error Bar: S.E.M.
Ruparel et al. Molecular Pain 2012, 8:73 Page 5 of 9
http://www.molecularpain.com/content/8/1/73
Figure 3 Release of TRPV1 agonists. A. Twenty-four hour old rat
TG cultures were pretreated with either vehicle or 30uM
ketoconazole for 15 minutes following which 1 mM LA with vehicle
or the same concentration of ketoconazole was applied to the
neurons for 2 minutes and calcium accumulated was tested by
measuring ratio of fluorescence produced at 340 and 380 nm
wavelengths. The experiment was performed with three
independent neuronal cultures and mean responses for each group
is plotted. Data were analyzed using 2-tailed student’s t-test. Error
Bars: S.E.M. Noise indicates basal fluorescence ratio 340/360 with
application of Hanks Buffer. B. Lipophilic extracts were made from
inflamed skin from rats, pretreated with vehicle or 18 mM
ketoconazole in vivo as well as vehicle or 150uM ketoconazole
ex vivo and applied onto 5-day old rat TG cultures for 15 minutes.
Neurons were pretreated with either vehicle or 1uM I-RTX for
15 minutes prior to extract application. The superfusates were
collected and subjected to radioimmunoassay for estimation of
CGRP release. Three independent experiments were performed and
data plotted is the mean of % release from baseline for each group.
Data were normalized such that baseline release from neurons was
made to be 100%. Data were analyzed using one-way ANOVA and
Neuman-Keuls post hoc test. Error Bars: S.E.M.
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inflammation is TRPV1 dependent
If the OLAM system is active during CFA inflammation,
then administration of exogenous LA to inflamed hind-
paws would be predicted to trigger nocifensive beha-
viors. In control (un-inflamed) hindpaws, the ipl
injection of LA did not produce a significant increase in
spontaneous nocifensive behaviors (Figure 4A). However,
at 24 h after CFA inflammation was established, the ipl
injection of LA produced a dose-dependent nocifensive
effect (Figure 4A). This suggests that the machinery re-
sponsible for OLAM synthesis is minimally active underFigure 4 Effect of Linoleic acid on Nocifensive Behavior in Rats
and Mice. A. Rats were injected either with saline or 1:1 CFA and
24 hours later, vehicle, 10, 100 or 1000ug linoleic acid was injected
into normal uninflamed and/or inflamed hindpaws and nocifensive
behavior was recorded upto 15 minutes. Data are plotted as total
nocifensive behavior time (in seconds) within 15 minutes. n = 6 was
used for each group. Data Analyzed using one-way ANOVA with
Neuman-Keuls post hoc test. Error Bar: S.E.M. B. Rats were injected
with 1:1 CFA and 24 hours later, 50 mg/kg capsazepine or vehicle
was injected systemically underneath the neck. 1 hour later, 1000ug
of LA was injected in the inflamed paws and nocifensive behavior
was recorded upto 15 minutes. Data plotted is the total nocifensive
time (in secs) observed between 8 and 15 minutes. n = 8 was used
for each group. Data analyzed using 2-tailed Student’s t-test. Error
Bar: S.E.M. C. Wild-type mice or TRPV1 KO mice were injected with
1:1 CFA and 24 hours later 1000ug LA was injected in the inflamed
paws of wild-type and TRPV1 KO mice. Nocifensive behavior was
recorded and plotted between 8 and 15 minutes after injection. A
vehicle group was included in the TRPV1 KO mice as well. Data
plotted is the total nocifensive time (in sec) observed between 8
and 15 minutes. n = 8 was used for each group. Data Analyzed
using one-way ANOVA with Neuman-Keuls post hoc test. Error Bar:
S.E.M.
Figure 5 Effect of anti-HODE Antibodies and Ketoconazole on
LA-evoked Nocifensive Behavior. A. Rats were injected with
1:1CFA and 24 hours later, were injected with either vehicle, control
IgG anti-goat antibody or mix of anti-9 and 13-HODE antibodies
(25ug each). Following 10 minutes, a second injection of either
vehicle or 1000ug LA was given and nocifensive behavior was
recorded upto 15 mins. Data plotted is the total nocifensive time
(secs) observed between 8 and 15 mins. n = 8/10 was used for each
group. Data analyzed using one-way ANOVA with Neuman-Keuls
post hoc test. Error Bar: S.E.M. B. Similar to data set 4A, rats were
injected with vehicle or 4ug ketoconazole as the first injection into
the inflamed paws and 30 minutes later, vehicle or 1000ug LA with
vehicle or 1000ug LA with 4ug ketoconazole was given as the
second injection. Data plotted is the total nocifensive time (secs)
observed between 8 and 15 mins. n = 8/10 was used for each
group. Data Analyzed using one-way ANOVA with Neuman-Keuls
post hoc test. Error Bar: S.E.M.
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lowing tissue inflammation. We next evaluated whether
LA-induced nocifensive behaviors in inflamed hindpaws
was mediated by activation of TRPV1. In rats, pretreat-
ment with capsazepine significantly reduced LA-evoked
nocifensive behaviors (Figure 4B). Similarly, LA-
triggered nocifensive behaviors were significantly
reduced in mice with genetic deletion of TRPV1 as com-
pared to wild type mice (Figure 4C). Thus, inflammation
enhances LA-induced nocifensive behaviors and these
behaviors are due, at least in part, to TRPV1 activity.
Since LA can be metabolized to various different poly-
unsaturated fatty acids (PUFAs) [19-23], we noted in our
preliminary studies the nocifensive effects of LA in vivo,
produced a TRPV1 dependent response between 8 and
15 minutes after LA injection. Hence in subsequent
experiments, we focused on this time range and there-
fore the data shown in Figure 4B, 4C and Figure 5 is
nocifensive behavior observed only between 8 and
15 minutes after LA injection.
Anti-HODE antibodies and Ketoconazole inhibit linoleic
acid-induced nocifensive behavior
We next evaluated whether administration of exogenous
LA triggers nocifensive behaviors via enzymatic forma-
tion of OLAMs. As seen in Figure 5A, the ipl injection
of a combination of anti-9 and anti-13-HODE antibodies
reduced LA-induced nocifensive behavior by ~72% com-
pared to the group that received either the control anti-
goat IgG antibody or the vehicle (HBSS) group.
Next, to further study the role of CYP enzymes in
OLAM synthesis, we pretreated the inflamed rat hind-
paws with ketoconazole 30 minutes prior to LA injection
and observed that ketoconazole also inhibited LA effect
by ~70% (Figure 5B).
Discussion
Oxidized metabolites of linoleic acid are elevated in in-
flammatory conditions such as atherosclerosis and
rheumatoid arthritis and chronic pancreatitis [6-9]. Re-
cently, our group has demonstrated that some of these
metabolites, namely, 9-HODE, 13-HODE and their oxo-
metabolites, are endogenous TRPV1 agonists [12,13].
The present study has expanded the knowledge of the
OLAMs by implicating their role in evoking inflamma-
tory heat hyperalgesia. Thus, OLAMs may not only me-
diate acute responses to thermal stimulation in sensory
neurons [12,13], but may also participate in more pro-
longed inflammatory conditions.
Several independent lines of evidence were pursued to
test this hypothesis. First, peripheral injection of anti-
HODE antibodies were shown to reverse inflammatory
heat hyperalgesia. Second, lipid extracts of inflamed hind
paw skin were shown to contain endogenous TRPV1agonists. Third, ketoconazole, a broadly acting inhibitor
of oxidative enzymes, was demonstrated to inhibit the
release of endogenous TRPV1 agonists from inflamed
skin, to inhibit CFA-induced heat hyperalgesia and to in-
hibit the effects of exogenous linoleic acid for triggering
spontaneous nocifensive behaviors. Collectively, these
data provide strong support for the hypothesis that
OLAMs contribute to inflammatory heat hyperalgesia.
An additional finding in this study is that exogenous
linoleic acid triggers spontaneous nocifensive behaviors
when injected into inflamed, but not control hind paw
tissue. This effect of linoleic acid was dose-related and
was due, in part, to activation of TRPV1 as indicated by
the use of capsazepine in rats and studies conducted in
TRPV1-/- mice. However, the data also reveal an add-
itional non-TRPV1 mechanism for linoleic acid-evoked
nocifensive behavior The effects of linoleic acid are
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anti-13-HODE antibodies, implicating these mediators
in contributing to spontaneous nocifensive behaviors.
Interestingly, this immunoneutralization experiment did
not completely block the nocifensive effects of linoleic
acid. This incomplete blockade might be due to the for-
mation of non-HODE OLAMs (e.g., 9-oxoODE or 13-
oxoODE), to a non-OLAM mechanism, or to insufficient
amount of antibodies (i.e., 1,000 ug of linoleic acid is ~3.5
umol versus ~0.3 nmol antibody). It is not likely that the
“non-OLAM” mechanism is due to protons, since the
linoleic acid solution and the vehicle were both buffered
to a pH of 7.4 prior to injection. Since linoleic acid can be
a substrate for the formation of epoxy-9Z-octadecenoic
acids, the corresponding dihydroxy acids, as well as ara-
chidonic acid and its metabolites, several potential non-
OLAM mediators are possible [19-21,23,24]. For example,
arachidonic acid metabolites such as 12- and 15-(S)-
hydroperoxyeicosatetraenoic acids, 5- and 15-(S)-hydro-
xyeicosatetraenoic acids as well as leukotriene B4 are class
of polyunsaturated fatty acids that are capable of activating
TRPV1 [4,5] It is notable that inflammation substantially
upregulates the machinery necessary for linoleic acid to
evoke spontaneous nocifensive behavior. One potential
mechanism is upregulation of oxidative enzymes capable
of metabolizing linoleic acid. This possibility is consistent
with the observation that ketoconazole significantly
reduces linoleic acid-evoked nocifensive behaviors. Indeed,
microarray studies have reported upregulation of several
CYPs after CFA injection [25], including CYP3A1, an en-
zyme expressed in about 40% of TRPV1+ neurons [14].
However, the results do not exclude the possibility
that the enhanced LA response could also be in part
due to changes in TRPV1 expression, trafficking or
phosphorylation.
This study also found that ketoconazole has an unex-
pected antihyperalgesic effect. This action of ketocona-
zole is peripherally mediated since injection into
contralateral hindpaws had no effect. The effect appears
to be due, at least in part, to inhibition of the OLAM
system, since ketoconazole blocked linoleic acid-induced
elevation in [Ca]i in cultured neurons and significantly
reduced linoleic acid-induced nocifensive behaviors in
rats. Moreover, treatment with ketoconazole inhibited
the release of endogenous TRPV1 agonists from
inflamed tissue. However, since ketoconazole inhibits
multiple oxidative enzymes including CYPs, the bio-
chemical mechanism of action requires future evalu-
ation. Taken together, the finding that ketoconazole only
acts in the injured area, suggests that it may serve as a
prototype for a novel class of peripherally active
analgesics.
Collectively, the current study implicates a role of
OLAMs in inducing inflammatory heat hyperalgesia inthe periphery and suggests that oxidative enzymes such
as cytochrome P450 isozymes play an important role in
OLAM synthesis. It would be worthwhile to study the
cell types in the skin tissue that are predominantly active
in the OLAM-CYP system. For example, several CYPs
and other oxidative enzymes are expressed in immune
cells [26,27] and we and others have demonstrated the
expression of several CYP isoforms in sensory neurons,
including the subpopulation that express TRPV1
[14,28,29]. Hence it is possible that OLAMs are synthe-
sized in the immune cells or neuronal terminals. The
finding that anti-OLAM antibodies reduced CFA-
induced heat hyperalgesia and linoleic acid-evoked noci-
fensive behaviors strongly support a paracrine function
of the OLAMs during tissue inflammation since it is not
likely that the antibodies cross plasma membranes. Iden-
tification of the cell type expressing these enzymes and
the specific isoforms driving OLAM synthesis may yield
potential targets for novel analgesic drug development.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
Dr. SR and Dr. KH designed all experiments. SR carried out in vitro
experiments with calcium imaging, lipid extract preparation and CGRP
radioimmunoassays as well as drafted the manuscript. Dr. KH edited the
manuscript as well as supervised the entire study. DG and PC performed
behavioral experiments. All authors read and approved the final manuscript.
Acknowledgements
The study was supported by NIH R01NS72890, R01DA019585, NCATS
UL1TR000149 and the American Pain Society Pain 2010 Future Leader’s Grant
(SR). The University of Texas has claimed intellectual property related to this
discovery.
Received: 18 June 2012 Accepted: 20 September 2012
Published: 24 September 2012
References
1. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR,
Koltzenburg M, Basbaum AI, Julius D: Impaired nociception and pain
sensation in mice lacking the capsaicin receptor. Science 2000,
288:306–313.
2. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries
MH, Latcham J, Clapham C, Atkinson K, et al: Vanilloid receptor-1 is
essential for inflammatory thermal hyperalgesia. Nature 2000,
405:183–187.
3. Planells-Cases R, Garcia-Sanz N, Morenilla-Palao C, Ferrer-Montiel A:
Functional aspects and mechanisms of TRPV1 involvement in
neurogenic inflammation that leads to thermal hyperalgesia. Pflugers
Arch 2005, 451:151–159.
4. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi
YH, Kim J, et al: Bradykinin-12-lipoxygenase-VR1 signaling pathway for
inflammatory hyperalgesia. Proc Natl Acad Sci U S A 2002, 99:10150–10155.
5. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG,
Kim D, Oh U: Direct activation of capsaicin receptors by products of
lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci
U S A 2000, 97:6155–6160.
6. Spiteller P, Spiteller G: 9-Hydroxy-10,12-octadecadienoic acid (9-HODE)
and 13-hydroxy-9,11-octadecadienoic acid (13-HODE): excellent markers
for lipid peroxidation. Chemistry and Physics of Lipids 1997, 89:131–139.
7. Jira W, Spiteller G, Richter A: Increased levels of lipid oxidation products in
low density lipoproteins of patients suffering from rheumatoid arthritis.
Chem Phys Lipids 1997, 87:81–89.
Ruparel et al. Molecular Pain 2012, 8:73 Page 9 of 9
http://www.molecularpain.com/content/8/1/738. Brooks CJ, Harland WA, Steel G, Gilbert JD: Lipids of human atheroma:
isolation of hydroxyoctade cadienoic acids from advanced aortal lesions.
Biochim Biophys Acta 1970, 202:563–566.
9. Stevens T, Berk MP, Lopez R, Chung YM, Zhang R, Parsi MA, Bronner MP,
Feldstein AE: Lipidomic profiling of serum and pancreatic fluid in chronic
pancreatitis. Pancreas 2012, 41:518–522.
10. Engels F, Drijver AA, Nijkamp FP: Modulation of the release of
9-hydroxy-octadecadienoic acid and other fatty acid derived mediators
from guinea-pig pulmonary macrophages. Int J Immunopharmacol 1990,
12:199–205.
11. Kaduce TL, Figard PH, Leifur R, Spector AA: Formation of
9-hydroxyoctadecadienoic acid from linoleic acid in endothelial cells.
J Biol Chem 1989, 264:6823–6830.
12. Patwardhan AM, Akopian AN, Ruparel NB, Diogenes A, Weintraub ST,
Uhlson C, Murphy RC, Hargreaves KM: Heat generates oxidized linoleic
acid metabolites that activate TRPV1 and produce pain in rodents. J Clin
Invest 2010, 120:1617–1626.
13. Patwardhan AM, Scotland PE, Akopian AN, Hargreaves KM: Activation of
TRPV1 in the spinal cord by oxidized linoleic acid metabolites
contributes to inflammatory hyperalgesia. Proc Natl Acad Sci U S A 2009,
106:18820–18824.
14. Ruparel S, Henry MA, Akopian A, Patil M, Zeldin DC, Roman L, Hargreaves
KM: Plasticity of cytochrome P450 isozyme expression in rat trigeminal
ganglia neurons during inflammation. Pain 2012, 153(10):2031–2039.
15. Akopian AN, Ruparel NB, Jeske NA, Hargreaves KM: Transient receptor
potential TRPA1 channel desensitization in sensory neurons is agonist
dependent and regulated by TRPV1-directed internalization. J Physiol
2007, 583:175–193.
16. Patwardhan AM, Diogenes A, Berg KA, Fehrenbacher JC, Clarke WP, Akopian
AN, Hargreaves KM: PAR-2 agonists activate trigeminal nociceptors and
induce functional competence in the delta opioid receptor. Pain 2006,
125:114–124.
17. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive
method for measuring thermal nociception in cutaneous hyperalgesia.
Pain 1988, 32:77–88.
18. Ruparel NB, Patwardhan AM, Akopian AN, Hargreaves KM: Homologous and
heterologous desensitization of capsaicin and mustard oil responses
utilize different cellular pathways in nociceptors. Pain 2008, 135:271–279.
19. Kegg P: Linoleic Acid Metabolism. http://www.genome.jp/kegg/pathway/
map/map00591.html.
20. Meves H: Arachidonic acid and ion channels: an update. Br J Pharmacol
2008, 155:4–16.
21. Sisignano M, Park CK, Angioni C, Zhang DD, von Hehn C, Cobos EJ,
Ghasemlou N, Xu ZZ, Kumaran V, Lu R, et al: 5,6-EET Is Released upon
Neuronal Activity and Induces Mechanical Pain Hypersensitivity via
TRPA1 on Central Afferent Terminals. J Neurosci 2012, 32:6364–6372.
22. Yu L, Yang F, Luo H, Liu FY, Han JS, Xing GG, Wan Y: The role of TRPV1 in
different subtypes of dorsal root ganglion neurons in rat chronic
inflammatory nociception induced by complete Freund's adjuvant. Mol
Pain 2008, 4:61.
23. Rachlin AI, Wasyliw N, Goldberg MW: Synthesis of Arachidonic Acid. J Org
Chem 1961, 26:2688–2693.
24. Gregus AM, Doolen S, Dumlao DS, Buczynski MW, Takasusuki T, Fitzsimmons
BL, Hua X-Y, Taylor BK, Dennis EA, Yaksh TL: Spinal 12-lipoxygenase-
derived hepoxilin A3 contributes to inflammatory hyperalgesia via
activation of TRPV1 and TRPA1 receptors. Proc Natl Acad Sci 2012,
109:6721–6726.
25. Spears R, Oakes R, Moore C, Bellinger LL, Hutchins B: A Determination of
Tumor Necrosis Factor Expression in TMJ Inflammation with the Use of
Microarray Analysis. J Dent Res 2003, 82:807–813.
26. Nakayama A, Riesen I, Kollner B, Eppler E, Segner H: Surface marker-defined
head kidney granulocytes and B lymphocytes of rainbow trout express
benzo[a]pyrene-inducible cytochrome P4501A protein. Toxicol Sci 2008,
103:86–96.
27. Bratland E, Skinningsrud B, Undlien DE, Mozes E, Husebye ES: T cell
responses to steroid cytochrome P450 21-hydroxylase in patients with
autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009,
94:5117–5124.28. Iliff JJ, Fairbanks SL, Balkowiec A, Alkayed NJ: Epoxyeicosatrienoic acids are
endogenous regulators of vasoactive neuropeptide release from
trigeminal ganglion neurons. J Neurochem 2010, 115:1530–1542.
29. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ: Epoxyeicosanoids as mediators of
neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol
2009, 296:H1352–H1363.
doi:10.1186/1744-8069-8-73
Cite this article as: Ruparel et al.: The cytochrome P450 inhibitor,
ketoconazole, inhibits oxidized linoleic acid metabolite-mediated
peripheral inflammatory pain. Molecular Pain 2012 8:73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
